Jianshun Bioscience to Distribute Cell-based Vaccine Technology in China

Jianshun Biosciences of Lanzhou signed an exclusive license to distribute Valneva's embryonic stem cell-based vaccine technology in China. Valneva, a French company, developed EB66® cell line as a cell-based medium to manufacture vaccines. Valneva received a $2.7 million upfront payment and is entitled to further annual license fees and royalties. Jianshun will keep 50% of all sub-license revenue. The agreement allows the EB66® line to be used for human and animal viral vaccines, but excludes any flu vaccines. More details.... Share this with colleagues: // //